Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Carisoprodol Tablets, Usp, 350 Mg
Generic Name
Carisoprodol
Active Ingredient
CarisoprodolCategory
Muscle Relaxant [EPC]
Variants
4
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 350 mg/1 | TABLET | ORAL | 63561-0127 |
| 350 mg/1 | TABLET | ORAL | 71335-3018 |
| 350 mg/1 | TABLET | ORAL | 72162-2525 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Carisoprodol Tablets, Usp, 350 Mg, you must consult a qualified healthcare professional.
| 350 mg/1 | TABLET | ORAL | 72789-477 |
Detailed information about Carisoprodol Tablets, Usp, 350 Mg
Carisoprodol is a centrally acting skeletal muscle relaxant indicated for the short-term relief of acute, painful musculoskeletal conditions in adults. It works by modulating neuronal communication in the central nervous system to alleviate discomfort.
For the treatment of acute, painful musculoskeletal conditions, the standard adult dosage of carisoprodol is typically 250 mg to 350 mg taken three times a day and at bedtime. This regimen results in a total daily dose of 1,000 mg to 1,400 mg. Healthcare providers generally emphasize that this medication should only be used for short durations, typically not exceeding two to three weeks. If symptoms persist beyond this timeframe, a re-evaluation of the underlying condition is necessary, as carisoprodol is not intended for chronic management.
Carisoprodol is not recommended for use in pediatric patients under the age of 16. The safety and effectiveness of this medication in children have not been established through rigorous clinical trials. The CNS-depressant effects and the potential for the metabolite meprobamate to accumulate present significant risks to developing neurological systems.
Carisoprodol and its metabolite meprobamate are primarily cleared by the kidneys. In patients with impaired renal function, there is a risk of drug accumulation, which can lead to increased toxicity and profound sedation. While specific dosage adjustment scales are not always provided by the manufacturer, healthcare providers usually exercise extreme caution, often opting for the lowest effective dose or avoiding the drug entirely in cases of severe renal failure or end-stage renal disease.
Since carisoprodol is extensively metabolized in the liver (via the CYP2C19 enzyme), hepatic impairment can significantly alter the drug's blood levels. Patients with liver disease may experience higher concentrations of the parent drug and a delayed conversion to meprobamate. Dosage should be approached with caution, and in cases of severe hepatic cirrhosis, the drug is often contraindicated.
Geriatric patients (aged 65 and older) are particularly sensitive to the sedative effects of carisoprodol. There is an increased risk of confusion, over-sedation, and falls, which can lead to hip fractures or other serious injuries. Clinical guidelines often suggest that carisoprodol be avoided in the elderly (as noted in the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults). If it must be used, the lowest possible dose (250 mg) is recommended for the shortest possible duration.
Carisoprodol should be taken exactly as prescribed by your healthcare provider. It can be taken with or without food; however, taking it with food may help decrease the likelihood of an upset stomach. The tablets should be swallowed whole with a full glass of water. You should not crush, chew, or break the tablets unless specifically instructed by your doctor, as this can alter the absorption rate. Because the medication causes significant drowsiness, the 'at bedtime' dose is particularly important for ensuring the patient can rest, but patients must be careful not to engage in activities requiring alertness immediately after any dose. Store the medication at room temperature, away from moisture, heat, and light, and ensure it is kept in a secure location to prevent unauthorized use or accidental ingestion by children.
If you miss a dose of carisoprodol, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this significantly increases the risk of over-sedation and respiratory depression.
An overdose of carisoprodol is a medical emergency. Symptoms of overdose include extreme drowsiness, ataxia (loss of muscle coordination), headache, blurred vision, hallucinations, and in severe cases, coma or respiratory depression. Because carisoprodol is often taken in combination with other substances, the risk of a fatal overdose is higher when combined with alcohol or opioids. If an overdose is suspected, call 911 or your local emergency services immediately. Emergency treatment typically involves supportive care, including airway management and intravenous fluids, as there is no specific pharmacological antagonist for carisoprodol.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or extend the duration of treatment without medical guidance, as this may lead to physical dependence or withdrawal symptoms upon discontinuation.
The most frequently reported side effects of carisoprodol involve the central nervous system, which is expected given its mechanism of action.
Carisoprodol is a potent central nervous system (CNS) depressant. The most critical safety information for any patient is the risk of profound sedation and impairment. Patients must be aware that the effects of this drug are cumulative when combined with other substances. Furthermore, carisoprodol has a well-documented potential for misuse and addiction. It should never be shared with others, and it should be kept in a locked cabinet if there are individuals in the household with a history of substance use disorder.
No FDA black box warnings for Carisoprodol as of the current 2026 labeling. However, clinicians are advised to follow the strict guidelines for Schedule IV substances.
There are certain medications that should never be used in conjunction with carisoprodol due to the extreme risk of adverse outcomes:
Absolute contraindications are conditions under which carisoprodol must never be prescribed because the risks clearly outweigh any possible benefit.
Carisoprodol is classified as FDA Pregnancy Category C (under the older system, though current 2026 labeling uses the Pregnancy and Lactation Labeling Rule). There are no adequate and well-controlled studies in pregnant women. Animal studies have shown that carisoprodol can cross the placenta and may cause decreased fetal weights and delayed skeletal ossification at doses that are toxic to the mother. Use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus. It is generally avoided during the first trimester when organogenesis (the formation of organs) is occurring.
Carisoprodol and its active metabolite, meprobamate, are excreted into human breast milk in high concentrations. In some cases, the concentration in breast milk can be two to four times higher than the concentration in the mother's blood. This can lead to excessive sedation, poor feeding, and respiratory issues in the nursing infant. Because of these risks, healthcare providers usually recommend that women either discontinue nursing or discontinue the drug. If the drug is necessary, the infant must be closely monitored for signs of CNS depression.
Carisoprodol is a centrally acting skeletal muscle relaxant. Its molecular mechanism is distinct from drugs like dantrolene, which acts directly on the muscle. Carisoprodol's primary effect is likely due to its action in the spinal cord and the descending reticular formation in the brain. It is believed to disrupt the interneuronal pool—the network of neurons that relay signals between the brain and the muscles. By inhibiting these interneurons, the drug reduces the transmission of excitatory signals that cause muscle spasms. Much of the clinical effect is also derived from meprobamate, which acts as a positive allosteric modulator of the GABA-A receptor, increasing chloride ion channel opening and causing hyperpolarization of the neuron, which leads to a generalized sedative effect.
The pharmacodynamics of carisoprodol are characterized by a rapid onset of CNS depression. The muscle relaxant effects typically begin within 30 minutes of oral administration and last for approximately 4 to 6 hours. There is a clear dose-response relationship; higher doses lead to more profound sedation rather than necessarily 'better' muscle relaxation. Over time, patients can develop tolerance to the sedative effects, which often leads to a dangerous desire to increase the dose to maintain the initial feeling of 'relaxation.'
Common questions about Carisoprodol Tablets, Usp, 350 Mg
Carisoprodol is primarily used for the short-term relief of acute, painful musculoskeletal conditions, such as muscle spasms or strains. It is intended to be used as an adjunct to rest, physical therapy, and other non-medication treatments. Healthcare providers typically prescribe it for durations of two to three weeks because there is no evidence of long-term effectiveness. It works by depressing the central nervous system rather than acting directly on the muscles. It is not used for chronic pain conditions like rheumatoid arthritis or long-term back pain. Always use this medication under the strict guidance of a medical professional.
The most common side effects of carisoprodol include significant drowsiness, dizziness, and headache. Many patients report feeling a heavy sense of sedation, which can make it difficult to perform daily tasks that require alertness. Some individuals may also experience a fast heartbeat (tachycardia) or an upset stomach. These effects are often most pronounced during the first few days of treatment. If you experience severe side effects like fainting, extreme confusion, or a loss of coordination, you should contact your doctor immediately. Because it is a CNS depressant, these side effects are intensified if the drug is taken with alcohol.
No, you should strictly avoid alcohol while taking carisoprodol. Both carisoprodol and alcohol are central nervous system depressants, and taking them together can lead to a dangerous additive effect. This combination significantly increases the risk of extreme sedation, respiratory depression, and even fatal overdose. Alcohol also speeds up the impairment of motor skills, making activities like driving or walking much more hazardous. Even small amounts of alcohol can interact poorly with the medication. Always discuss your alcohol consumption habits with your doctor before starting this treatment.
Carisoprodol is generally not recommended during pregnancy unless the potential benefits clearly outweigh the risks to the fetus. It is classified as a medication that should be used with caution because it can cross the placenta and affect the developing baby. There is limited data on human pregnancy, but animal studies have suggested potential risks like decreased birth weight. It is particularly important to avoid use during the first trimester if possible. If you are pregnant or planning to become pregnant, your healthcare provider will likely suggest safer alternatives for managing muscle pain. Breastfeeding is also discouraged as the drug passes into breast milk in high amounts.
Carisoprodol works relatively quickly, with most patients feeling the effects within 30 minutes of taking an oral dose. The peak concentration of the drug in the bloodstream is usually reached between 1.5 and 2 hours after ingestion. The relief provided by a single dose typically lasts for about 4 to 6 hours. Because of this quick onset, it is often prescribed to be taken three times a day and at bedtime. However, you should not take doses more frequently than prescribed even if you feel the effect wearing off. If the medication does not seem to be working, consult your doctor rather than increasing the dose yourself.
You should not stop taking carisoprodol suddenly if you have been using it for more than a few days or at high doses. Abrupt discontinuation can lead to withdrawal symptoms because the body may have developed a physical dependence on the drug. Withdrawal symptoms can include anxiety, insomnia, tremors, muscle cramps, and in rare cases, seizures or hallucinations. If you need to stop the medication, your healthcare provider will typically provide a tapering schedule to slowly reduce the dose. This gradual reduction helps your central nervous system adjust safely. Always follow your doctor's specific instructions for ending your treatment.
If you miss a dose of carisoprodol, you should take it as soon as you remember. However, if it is nearly time for your next scheduled dose, it is better to skip the missed dose entirely and continue with your regular schedule. You should never take two doses at the same time to 'make up' for a missed one. Taking a double dose significantly increases the risk of over-sedation and dangerous side effects. If you find yourself frequently missing doses, consider setting a reminder on your phone. Consistent dosing is important for maintaining the therapeutic effect while minimizing risks.
Weight gain is not a commonly reported side effect of carisoprodol, especially given its intended short-term use of two to three weeks. Most clinical trials do not list weight changes as a significant adverse reaction to the medication. However, because the drug causes significant drowsiness and sedation, it may lead to decreased physical activity, which could indirectly contribute to weight changes if used for longer than recommended. If you notice significant or rapid weight gain while taking this medication, it may be due to another underlying cause or a different medication. You should discuss any unexpected physical changes with your healthcare provider.
Carisoprodol has many significant drug interactions, particularly with other medications that affect the central nervous system. It should be used with extreme caution if you are taking opioids, benzodiazepines, or sleep medications, as these combinations can be fatal. It also interacts with certain enzymes in the liver, meaning drugs like omeprazole or certain antidepressants can change how carisoprodol is processed. Even over-the-counter supplements like St. John's Wort can interfere with its effectiveness. Always provide your doctor with a complete list of all medications and supplements you are currently taking. This allows them to screen for potentially dangerous interactions before you start carisoprodol.
Yes, carisoprodol is widely available as a generic medication, which is typically much more affordable than the brand-name version, Soma. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. They must also prove bioequivalence, meaning they work in the body the same way. Most insurance plans prefer the generic version of carisoprodol. Whether you are prescribed the brand or the generic, the safety precautions, side effects, and dosage instructions remain identical. Your pharmacist can help you determine which version is covered by your specific insurance plan.
Other drugs with the same active ingredient (Carisoprodol)
> Warning: Stop taking Carisoprodol and call your doctor immediately if you experience any of these serious symptoms.
Carisoprodol is not intended for long-term use, and doing so can lead to several chronic issues:
As of 2026, carisoprodol does not carry a specific FDA Black Box Warning. However, it does carry significant 'Warnings and Precautions' regarding its potential for abuse, its status as a controlled substance, and the dangers of combining it with other CNS depressants like opioids or benzodiazepines. The clinical community treats the risks of carisoprodol with the same level of gravity as medications that do carry black box warnings, particularly regarding the 'Holy Trinity' of drug combinations (opioid + benzodiazepine + carisoprodol), which is associated with a high risk of fatal respiratory depression.
Report any unusual symptoms to your healthcare provider. Timely reporting of side effects helps in adjusting your treatment plan and preventing serious complications.
While carisoprodol is intended for short-term use, certain monitoring may be required if the clinical situation is complex:
Patients taking carisoprodol should not drive, operate heavy machinery, or engage in any hazardous activities until they know how the medication affects them. The sedation caused by carisoprodol can be unpredictable and may be more severe than the patient realizes, leading to 'sleep-driving' or other dangerous behaviors.
Alcohol must be strictly avoided while taking carisoprodol. Both substances are CNS depressants. When taken together, they produce a synergistic effect, meaning the total sedation is much greater than the sum of the individual effects. This combination can lead to fatal respiratory depression, where the brain 'forgets' to tell the lungs to breathe.
If carisoprodol has been taken for more than a few weeks, it should not be stopped abruptly. A gradual tapering schedule, supervised by a healthcare provider, is necessary to avoid withdrawal symptoms. Withdrawal can manifest as insomnia, vomiting, abdominal cramps, headache, tremors, and in severe cases, hallucinations or seizures.
> Important: Discuss all your medical conditions, including any history of drug or alcohol addiction, with your healthcare provider before starting Carisoprodol.
Carisoprodol and meprobamate can occasionally interfere with certain laboratory tests:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the best way to prevent dangerous drug interactions.
Relative contraindications require a careful risk-benefit analysis by the healthcare provider.
Patients who are allergic to meprobamate will almost certainly be allergic to carisoprodol. Additionally, patients who have had severe reactions to other carbamate derivatives (a specific chemical class of medications) should be evaluated for potential cross-sensitivity before starting carisoprodol.
> Important: Your healthcare provider will evaluate your complete medical history, including rare genetic conditions and past drug reactions, before prescribing Carisoprodol.
Patients over the age of 65 are at a significantly higher risk when taking carisoprodol. The physiological changes associated with aging—such as reduced liver blood flow and decreased glomerular filtration rate (kidney function)—lead to a slower clearance of the drug. This results in prolonged sedation and an increased risk of 'drug-induced delirium.' The risk of falls is a primary concern, as a fall in an elderly patient can lead to a loss of independence or life-threatening complications. Most 2026 clinical guidelines recommend alternative treatments for musculoskeletal pain in the elderly.
In patients with a reduced Glomerular Filtration Rate (GFR), the excretion of meprobamate is significantly delayed. Patients with mild to moderate renal impairment may require longer intervals between doses. For those with a GFR below 30 mL/min, carisoprodol is generally not recommended. The drug is dialyzable, meaning it can be removed by hemodialysis, but this is usually only relevant in cases of overdose.
Since the liver is the primary site of carisoprodol's transformation into meprobamate, any degree of liver failure can lead to unpredictable drug levels. In patients with Child-Pugh Class B or C hepatic impairment, the drug's half-life can be significantly extended. Healthcare providers will typically avoid carisoprodol in these patients to prevent hepatic encephalopathy (brain dysfunction caused by liver failure) or profound CNS depression.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have any underlying organ dysfunction.
| Parameter | Value |
|---|---|
| Bioavailability | High (Rapidly absorbed from the GI tract) |
| Protein Binding | Approximately 60% |
| Half-life | 2 hours (Carisoprodol); 10–15 hours (Meprobamate) |
| Tmax | 1.5 to 2 hours |
| Metabolism | Hepatic via CYP2C19 enzyme |
| Excretion | Renal (95% as metabolites) |
Carisoprodol is a carbamic acid ester with the molecular formula C12H24N2O4 and a molecular weight of 260.33 g/mol. It is a white, crystalline powder with a mild, characteristic odor and a bitter taste. It is slightly soluble in water but freely soluble in alcohol and acetone. Its structure is chemically related to the tranquilizer meprobamate, differing only by the addition of an isopropyl group on one of the nitrogen atoms.
Carisoprodol is classified as a skeletal muscle relaxant. Within this broad category, it is further specified as a carbamate derivative. It is therapeutically related to other muscle relaxants such as cyclobenzaprine (a tricyclic derivative) and methocarbamol, though its pharmacological profile is more closely aligned with sedative-hypnotics due to its meprobamate metabolite.